MG
TSHA icon

Michael Gelband’s Taysha Gene Therapies TSHA Stock Holding History

Michael Gelband’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-148,357
Closed -$343K – 2033
2025
Q2 		$343K Buy
+148,357
New +$322K ﹤0.01% 1223
2024
Q4 		– Sell
-68,264
Closed -$137K – 2070
2024
Q3 		$137K Buy
+68,264
New +$150K ﹤0.01% 1495
2024
Q2 		– Sell
-112,077
Closed -$322K – 1994
2024
Q1 		$322K Buy
+112,077
New +$234K ﹤0.01% 1246
2020
Q4 		– Sell
-13,015
Closed -$292K – 2382
2020
Q3 		$292K Buy
+13,015
New +$306K 0.01% 1302

Other funds holding TSHA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Michael Gelband's TSHA Position: Q3 2025 in Review

Michael Gelband sold out of Taysha Gene Therapies (TSHA) in Q3 2025, closing a stake of 148,357 shares — an estimated $343K sold.

Michael Gelband first reported a position in TSHA in Q3 2020 and held it in 4 quarters. The position peaked at $343K in Q2 2025. 155 funds tracked by Wall St. Rank hold TSHA as of Q3 2025.

  • Michael Gelband reported no remaining Taysha Gene Therapies position as of Q3 2025 after selling out during the quarter.
  • Michael Gelband sold 148,357 Taysha Gene Therapies shares in Q3 2025, an estimated $343K.
  • Michael Gelband first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 4 quarters.
  • Michael Gelband's Taysha Gene Therapies position peaked at $343K in Q2 2025.
  • 155 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.